{"id":3724,"date":"2016-09-25T11:05:45","date_gmt":"2016-09-25T11:05:45","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3724"},"modified":"2016-09-25T11:05:45","modified_gmt":"2016-09-25T11:05:45","slug":"plazeboeffekte-in-der-therapie-des-typ-2-diabetes","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/","title":{"rendered":"Plazeboeffekte in der Therapie des Typ-2-Diabetes"},"content":{"rendered":"<p>AMB 2016, 50, 65 Plazeboeffekte in der Therapie des Typ-2-Diabetes Zusammenfassung: Eine aktuelle Metaanalyse ergibt Hinweise darauf, dass bei der medikament\u00f6sen Therapie von Patienten mit Typ-2-Diabetes bedeutsame Plazeboeffekte auf \u201eharte Endpunkte\u201c wie Gewichtsreduktion und HbA1c-Werte bestehen. Dabei verhalten sich die Plazebowirkungen in ihrer Art gleichsinnig wie die Wirkungen des Antidiabetikums. Das gilt auch f\u00fcr die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2016, 50, 65 Plazeboeffekte in der Therapie des Typ-2-Diabetes Zusammenfassung: Eine aktuelle Metaanalyse ergibt Hinweise darauf, dass bei der medikament\u00f6sen Therapie von Patienten mit Typ-2-Diabetes bedeutsame Plazeboeffekte auf \u201eharte Endpunkte\u201c wie Gewichtsreduktion und HbA1c-Werte bestehen. Dabei verhalten sich die Plazebowirkungen in ihrer Art gleichsinnig wie die Wirkungen des Antidiabetikums. Das gilt auch f\u00fcr die [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2470,1740,160,2468,2193,280,233,851,163,281,282,166,372,555,222,373,223,2469,224],"class_list":["post-3724","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alogliptin-dapagliflozin","tag-canagliflozin","tag-diabetes-mellitus-typ-2","tag-dulaglutid","tag-empagliflozin","tag-exenatid","tag-gliptine","tag-glucagon-like-peptide","tag-inkretinmimetika","tag-linagliptin","tag-liraglutid","tag-lixisenatid","tag-natrium-glukose-cotransporter-2","tag-plazebo","tag-saxagliptin","tag-sglt-2","tag-sitagliptin","tag-taspoglutid","tag-vildagliptin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plazeboeffekte in der Therapie des Typ-2-Diabetes<\/title>\n<meta name=\"description\" content=\"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plazeboeffekte in der Therapie des Typ-2-Diabetes\" \/>\n<meta property=\"og:description\" content=\"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-25T11:05:45+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Plazeboeffekte in der Therapie des Typ-2-Diabetes\",\"datePublished\":\"2016-09-25T11:05:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/\"},\"wordCount\":256,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Alogliptin Dapagliflozin\",\"Canagliflozin\",\"Diabetes mellitus Typ 2\",\"Dulaglutid\",\"Empagliflozin\",\"Exenatid\",\"Gliptine\",\"Glucagon-like peptide\",\"Inkretinmimetika\",\"Linagliptin\",\"Liraglutid\",\"Lixisenatid\",\"Natrium-Glukose-Cotransporter-2\",\"Plazebo\",\"Saxagliptin\",\"SGLT-2\",\"Sitagliptin\",\"Taspoglutid\",\"Vildagliptin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/\",\"name\":\"Plazeboeffekte in der Therapie des Typ-2-Diabetes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2016-09-25T11:05:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plazeboeffekte in der Therapie des Typ-2-Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plazeboeffekte in der Therapie des Typ-2-Diabetes","description":"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/","og_locale":"de_DE","og_type":"article","og_title":"Plazeboeffekte in der Therapie des Typ-2-Diabetes","og_description":"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2016-09-25T11:05:45+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Plazeboeffekte in der Therapie des Typ-2-Diabetes","datePublished":"2016-09-25T11:05:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/"},"wordCount":256,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Alogliptin Dapagliflozin","Canagliflozin","Diabetes mellitus Typ 2","Dulaglutid","Empagliflozin","Exenatid","Gliptine","Glucagon-like peptide","Inkretinmimetika","Linagliptin","Liraglutid","Lixisenatid","Natrium-Glukose-Cotransporter-2","Plazebo","Saxagliptin","SGLT-2","Sitagliptin","Taspoglutid","Vildagliptin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/","name":"Plazeboeffekte in der Therapie des Typ-2-Diabetes","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2016-09-25T11:05:45+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Plazeboeffekte in der Therapie des Typ-2-Diabetes -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/plazeboeffekte-in-der-therapie-des-typ-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Plazeboeffekte in der Therapie des Typ-2-Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3724"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3724\/revisions"}],"predecessor-version":[{"id":3725,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3724\/revisions\/3725"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}